We are live on ! Find out more
TLC

Taiwan Liposome
TLC

Delisted

TLC was delisted on the 28th of September, 2021.

7 hedge funds and large institutions have $3.58M invested in Taiwan Liposome in 2019 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 7 → 7 (0)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

99% less capital inflows, than outflows

Capital inflows: $8.64K | Capital outflows: $1.46M

Holders
7
Holders Change
–
Holders Change %
0%
% of All Funds
0.15%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
–
Increased
2
Reduced
2
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$6.96K
2
Advisor Group
Advisor Group
Arizona
+$1.68K

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$1.44M
2
Millennium Management
Millennium Management
New York
-$19K

TLC Hedge Fund Activity: Q2 2019 in Review

7 of the 4,627 institutional investors tracked by Wall St. Rank reported a position in Taiwan Liposome (TLC) for Q2 2019, worth a combined $3.58M — down 34% from $5.46M a quarter earlier.

Fund positioning in TLC was balanced in Q2 2019: 0 funds opened new positions, 0 closed out, 2 added to existing stakes and 2 trimmed.

The largest buyer was UBS Group, adding an estimated $6.96K. The largest seller was Morgan Stanley, cutting an estimated $1.44M.

  • 7 institutional investors held Taiwan Liposome (TLC) as of Q2 2019, unchanged from Q1 2019.
  • Funds reported $3.58M of Taiwan Liposome stock for Q2 2019, down 34% quarter-over-quarter.
  • 0 funds opened new Taiwan Liposome positions in Q2 2019 and 0 closed out.
  • The largest Taiwan Liposome buyer in Q2 2019 was UBS Group, an estimated $6.96K added.
  • The largest Taiwan Liposome seller in Q2 2019 was Morgan Stanley, an estimated $1.44M sold.

Based on aggregated 13F filings for Q2 2019.